Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9(®) to Suppress Enzalutamide-resistant Prostate Cancer Progression

Lignende værker

• Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer
  af: Chou, Fu-Ju, et al.
  Udgivet: (2020)
• Differential Androgen Deprivation Therapies with Anti-androgens Casodex/Bicalutamide or MDV3100/Enzalutamide versus Anti-androgen Receptor ASC-J9® Lead to Promotion versus Suppression of Prostate Cancer Metastasis
  af: Lin, Tzu-Hua, et al.
  Udgivet: (2013)
• Correction: Differential androgen deprivation therapies with anti-androgens Casodex/bicalutamide or MDV3100/enzalutamide versus anti-androgen receptor ASC-J9(®) lead to promotion versus suppression of prostate cancer metastasis
  af: Lin, Tzu-Hua, et al.
  Udgivet: (2020)
• Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells
  af: Lin, Changyi, et al.
  Udgivet: (2020)
• Anti-androgen therapy with Hydroxyflutamide or androgen receptor degradation enhancer ASC-J9(®) enhances BCG efficacy to better suppress bladder cancer progression
  af: Shang, Zhiqun, et al.
  Udgivet: (2015)